Fixed-dose combinations of insulin (like 70/30, 75/25 and 50/50) are more frequently associated with hypoglycemia than basal-bolus regimens for inpatients.
To reduce this risk, P&T authorized Pharmacy to remove combination insulins from the formulary. Starting on Oct. 14, new orders will need to be changed to levemir + aspart or separate orders for NPH and aspart. The pop-up will have suggestions on how to transition from a mixed insulin to a basal-bolus regimen.
If you have questions or concerns, please contact Matt Tanner (503-814-9960), Sandy Bunn or Michelle Grove.